[1]张海鹏,鲍启德,周利霞,等.吉非替尼联合奥沙利铂对人肝癌细胞SMMC-7721增殖和凋亡的影响[J].新乡医学院学报,2019,36(12):1115-1120.[doi:10.7683/xxyxyxb.2019.12.004]
　ZHANG Hai-peng,BAO Qi-de,ZHOU Li-xia,et al.Effect of gefitinib combined with oxaliplatin on proliferation and apoptosis of human hepatoma cell SMMC-7721[J].Journal of Xinxiang Medical University,2019,36(12):1115-1120.[doi:10.7683/xxyxyxb.2019.12.004]
点击复制

吉非替尼联合奥沙利铂对人肝癌细胞SMMC-7721增殖和凋亡的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
36
期数:
2019年12
页码:
1115-1120
栏目:
基础研究
出版日期:
2019-12-12

文章信息/Info

Title:
Effect of gefitinib combined with oxaliplatin on proliferation and apoptosis of human hepatoma cell SMMC-7721
作者:
张海鹏; 鲍启德; 周利霞; 孙李凌; 刘军清; 赵　越
（安阳地区医院肿瘤科，河南　安阳　455000）
Author(s):
ZHANG Hai-peng; BAO Qi-de; ZHOU Li-xia; SUN Li-ling; LIU Jun-qing; ZHAO Yue
(Department of Oncology，Anyang District Hospital，Anyang 455000，Henan Province，China)
关键词:
吉非替尼; 奥沙利铂; 肝细胞癌; 细胞凋亡
Keywords:
gefitinib;  oxaliplatin;  hepatocellular carcinoma; apoptosis
分类号:
R735.7
DOI:
10.7683/xxyxyxb.2019.12.004
文献标志码:
A
摘要:
目的　观察吉非替尼联合奥沙利铂对人肝癌细胞株SMMC-7721细胞增殖及凋亡的影响。方法　取对数生长期SMMC-7721细胞随机分为对照组、吉非替尼组、10 mg·L-1 奥沙利铂组、20 mg·L-1奥沙利铂组、40 mg·L-1奥沙利铂组、吉非替尼+10 mg·L-1奥沙利铂组、吉非替尼+20 mg·L-1奥沙利铂组及吉非替尼+40 mg·L-1奥沙利铂组共8组，依次加二甲基亚砜、2×10-6 mol·L-1吉非替尼、10 mg·L-1 奥沙利铂、20 mg·L-1 奥沙利铂、40 mg·L-1 奥沙利铂、2×10-6 mol·L-1吉非替尼和10 mg·L-1奥沙利铂、2×10-6 mol·L-1吉非替尼和20 mg·L-1奥沙利铂、2×10-6 mol·L-1吉非替尼和40 mg·L-1奥沙利铂各100 μL，每组设5个复孔。采用四甲基偶氮唑盐比色法测各组细胞给药后24、48、72 h的细胞生长抑制率。另取对数生长期SMMC-7721细胞分为对照组、吉非替尼组、20 mg·L-1 奥沙利铂组、吉非替尼+20 mg·L-1奥沙利铂组。吉非替尼组细胞加入 2×10-6 mol·L-1吉非替尼100 μL，奥沙利铂组细胞加入 20 mg·L-1 奥沙利铂100 μL，吉非替尼+20 mg·L-1奥沙利铂组细胞加入2×10-6 mol·L-1吉非替尼100 μL和 20 mg·L-1 奥沙利铂100 μL，对照组细胞加入等体积培养液。采用流式细胞术检测4组细胞给药后48 h的细胞周期和细胞凋亡率。结果　吉非替尼组和10 mg·L-1 奥沙利铂组在24 h时细胞抑制率与对照组比较差异无统计学意义（P>0.05）；其余各组在各时间点细胞抑制率均高于对照组（P<0.05）。3个联合组各时间点细胞抑制率均高于吉非替尼组（P<0.05），吉非替尼+10 mg·L-1奥沙利铂组各时间点细胞抑制率均高于10 mg·L-1奥沙利铂组（P<0.05），吉非替尼+20 mg·L-1奥沙利铂组各时间点细胞抑制率高于吉非替尼组和 20 mg·L-1奥沙利铂组（P<0.05），吉非替尼+40 mg·L-1奥沙利铂组各时间点细胞抑制率高于吉非替尼组和40 mg·L-1奥沙利铂组（P<0.05）。吉非替尼+10 mg·L-1 奥沙利铂组、吉非替尼+20 mg·L-1 奥沙利铂组和吉非替尼+40 mg·L-1 奥沙利铂组各时间点细胞抑制率成逐渐增高趋势，3组之间细胞抑制率两两比较差异均有统计学意义（P<0.05）。24 h时，吉非替尼+10 mg·L-1 奥沙利铂组与40 mg·L-1奥沙利铂组细胞抑制率比较差异无统计学意义（P>0.05）；48、72 h时，吉非替尼+10 mg·L-1 奥沙利铂组细胞抑制率高于40 mg·L-1奥沙利铂组（P<0.05）；吉非替尼+10 mg·L-1 奥沙利铂组在各时间点细胞抑制率均高于20 mg·L-1奥沙利铂组（P<0.05）。吉非替尼+20 mg·L-1 奥沙利铂组在各时间点细胞抑制率均高于40 mg·L-1奥沙利铂组（P<0.05）。吉非替尼组、10、20、40 mg·L-1 奥沙利铂组细胞抑制率组内各时间点比较差异无统计学意义（P>0.05）。吉非替尼+10 mg·L-1 奥沙利铂组和吉非替尼+40 mg·L-1 奥沙利铂组48、72 h时细胞抑制率均高于24 h（P<0.05）；2组在48 h和72 h时细胞抑制率比较差异均无统计学意义（P>0.05）。吉非替尼+20 mg·L-1 奥沙利铂组随作用时间增加细胞抑制率逐渐增加，各时间点两两比较差异均有统计学意义（P< 0.05）。吉非替尼组、20 mg·L-1奥沙利铂组和吉非替尼+20 mg·L-1奥沙利铂组细胞的细胞周期分布与对照组比较差异有统计学意义（P<0.05）。20 mg·L-1奥沙利铂组和吉非替尼+20 mg·L-1奥沙利铂组处于G0/G1期细胞比例低于吉非替尼组（P<0.05），处于S期细胞比例高于吉非替尼组（P<0.05）；吉非替尼组和 20 mg·L-1奥沙利铂组处于G2/M期细胞的比例比较差异无统计学意义（P>0.05）；吉非替尼+20 mg·L-1奥沙利铂组处于G2/M期细胞的比例高于吉非替尼组和20 mg·L-1奥沙利铂组(P<0.05)。吉非替尼组、20 mg·L-1奥沙利铂组和吉非替尼+20 mg·L-1奥沙利铂组细胞凋亡率均高于对照组 (P<0.05);吉非替尼组、20 mg·L-1奥沙利铂组细胞凋亡率比较差异无统计学意义（P>0.05）;吉非替尼+20 mg·L-1奥沙利铂组细胞凋亡率高于吉非替尼组、20 mg·L-1奥沙利铂组 (P<0.05)。结论　吉非替尼和奥沙利铂均可抑制肝癌细胞株 SMMC-7721 的生长和诱导细胞凋亡，吉非替尼联合奥沙利铂后细胞抑制作用明显增强，二者有协同作用。
Abstract:
Objective　To observe the effect of gefitinib combined with oxaliplatin on proliferation and apoptosis of human hepatoma cell line SMMC-7721.Methods　SMMC-7721cells in logarithmic phase were divided into control group，gefitinib group，10 mg·L-1oxaliplatin group，20 mg·L-1 oxaliplatin group，40 mg·L-1oxaliplatin group，gefitinib+10 mg·L-1 oxaliplatin group，gefitinib+20 mg·L-1 oxaliplatin group and gefitinib+40 mg·L-1 oxaliplatin group;five holes was set up in each group.The cells in above eight groups were added with dimethyl sulfoxide 100 μL，2×10-6 mol·L-1 gefitinib 100 μL，10 mg·L-1 oxaliplatin 100 μL，20 mg·L-1 oxaliplatin 100 μL，40 mg·L-1 oxaliplatin 100 μL,gefitinib and 10 mg·L-1oxaliplatin 100 μL，gefitinib and 20 mg·L-1oxaliplatin 100 μL，gefitinib and 40 mg·L-1 oxaliplatin 100 μL in turn.The growth inhibition ratio of cells at 24，48，72 h after administration were detected by methyl thiazdyl tetrazolium colorimetry in each group.In addition，SMMC-7721 cells in logarithmic phase were divided into control group，gefitinib group，20 mg·L-1 oxaliplatin group and gefitinib + 20 mg·L-1oxaliplatin group.The cells in gefitinib group were added with 2×10-6 mol·L-1 gefitinib 100 μL,the cells in oxaliplatin group were added with 20 mg·L-1 oxaliplatin 100 μL,the cells in gefitinib + 20 mg·L-1oxaliplatin group were added with 2×10-6 mol·L-1 gefitinib 100 μL and 20 mg·L-1oxaliplatin 100 μL，the cells in control group were added with equal volume of culture medium.The cell cycle and apoptosis rate at 48 hours after administration in the above four groups were detected by flow cytometry.Results　There was no significant difference in cell inhibition rate between gefitinib group，10 mg·L-1 oxaliplatin group and control group at 24 h (P>0.05); the cell inhibition rates in another groups were higher than those in the control group at each time point (P<0.05).The cell inhibition rates of the three combined groups were higher than those in the gefitinib group at each time point (P<0.05);the cell inhibition rate in gefitinib + 10 mg·L-1 oxaliplatin group was higher than that in the 10 mg·L-1 oxaliplatin group at each time point (P<0.05);the cell inhibition rate in gefitinib + 20 mg·L-1 oxaliplatin group was higher than that in the gefitinib group and 20 mg·L-1 oxaliplatin group at each time point (P<0.05);the cell inhibition rate in gefitinib + 40 mg·L-1 oxaliplatin group was higher than that in the gefitinib group and 40 mg·L-1 oxaliplatin group at each time point (P<0.05);the cell inhibition rates in gefitinib + 10 mg·L-1 oxaliplatin group，gefitinib + 20 mg·L-1 oxaliplatin group and gefitinib + 40 mg·L-1 oxaliplatin group increased gradually at each time point，and there was significant difference among the three groups (P<0.05).There was no significant difference in the cell inhibition rate between gefitinib + 10 mg·L-1 oxaliplatin group and 40 mg·L-1 oxaliplatin group at 24 h(P>0.05);the cell inhibition rate of gefitinib + 10 mg·L-1 oxaliplatin group was higher than that in the 40 mg·L-1 oxaliplatin group at 48,72 h (P< 0.05); the cell inhibition rate of gefitinib + 10 mg·L-1 oxaliplatin group was higher than that in the 20 mg·L-1 at each time point(P< 0.05).The cell inhibition rate of gefitinib + 20 mg·L-1 oxaliplatin group was higher than that in the 40 mg·L-1 oxaliplatin group at each time point(P< 0.05).There was no significant difference in the cell inhibition rate between each time point in gefitinib group，10,20,40 mg·L-1 oxaliplatin group (P>0.05).The cell inhibition rates of gefitinib + 10 mg·L-1 oxaliplatin group and gefitinib + 40 mg·L-1 oxaliplatin group at 48,72 h were higher than those at 24 h (P<0.05); there was no significant difference in the cell inhibition rates between 48 h and 72 h in the two groups (P>0.05).Conclusion　Both gefitinib and oxaliplatin can inhibit the growth and induce apoptosis of SMMC-7721 cell line.The inhibitory effect of gefitinib combined with oxaliplatin on SMMC-7721 cell line is significantly enhanced，and they have synergistic effect.

参考文献/References:

［1］　SHENG P，ZHANG M，ZHAO J，et al.Liver resection for intermediate hepatocellular carcinoma［J］.World J Hepatol，2016，8(14):607-615.
［2］　MARIN J，BRIZ O，HERRAEZ E，et al.Molecular bases of the poor response of liver cancer to chemotherapy［J］.Clin Res Hepatol Gas，2018,42(3):182-192.
［3］　刘景，徐晶，丁剑午.ATRA联合奈达铂对人肝癌细胞株Huh-7增殖与凋亡的影响［J］.世界华人消化杂志，2010，18(24):2538-2544.
［4］　SATOMURA H ，NAKAJIMA M ，SASAKI K，et al.Phase I doseescalation study of docetaxel，cisplatin，and 5-fluorouracil combination chemotherapy in patients with advanced esophageal carcinoma［J］.Int Surg，2015，100(6):1153-1158.
［5］　张琳刚，刘静.维生素C对奥沙利铂诱导胃癌BGC-823细胞的增殖抑制和诱导凋亡作用研究［J］.中国全科医学，2016,19(S1):80-82.
［6］　TAKAOKA E，KAWAI K，ANDO S，et al.Neutropenic colitis during standard dose combina-tion chemotherapy with nedaplatin and irinotecan for testicular cancer ［J］.Jpn J Clin Oncol，2006，36(1):60-63.
［7］　张海鹏，杨家梅，张嵩，等.全反式维甲酸联合奥沙利铂对人SMMC-7721肝癌细胞株的作用［J］.世界华人消化杂志，2012，20(10):851-855.
［8］　肖雪珍,袁东方,辛丹丹,等.Aglaroxin C对肝癌细胞体内外生长的抑制作用［J］.新乡医学院学报,2018,35(9):761-765，770.
［9］　CHLAPEK P，NERADIL J，REDOVA M，et al.The ATRA-induced differentiation of medulloblastoma cells is enhanced with LOX/COX inhibitors: an analysis of gene expression［J］.Cancer Cell Int，2014，14(1):51.
［10］　MATRKA M，HENNIGAN R，KAPPES F，et al.DEK over-ex-pression promotes mitotic defects and micronucleus formation［J］．Cell Cycle，2015，14(24):3939-3953．
［11］　KANDA M，SUGIMOTO H，KODERA Y.Genetic and epigeneticaspects of initiation and progression of hepatocellular carcinoma［J］.World J Gastroentero，2015，21(37):10584-10597．
［12］　PRIVETTE L，BENIGHT N，WAGH P，et al.The DEK oncogene promotes cellular proliferation through parac-rine Wnt signaling in Ron receptor positive breast cancers［J］.Oncogene，2015，34(18):2325-2336．

相似文献/References:

[1]张占东,郑育娟,袁媛,等.奥沙利铂联合卡培他滨新辅助化学疗法治疗中晚期胃癌疗效观察[J].新乡医学院学报,2012,29(09):703.
[2]王荦楠杨 萌崔艳慧张清琴,苗战会李小瑞,寇小格.奥沙利铂联合卡培他滨治疗晚期肝细胞癌的疗效及安全性 [J].新乡医学院学报,2012,29(10):787.
[3]熊万成,平贯芳,贺德栋,等.雷公藤甲素对人结直肠癌细胞奥沙利铂耐药性的影响[J].新乡医学院学报,2023,40(7):613.[doi:10.7683/xxyxyxb.2023.07.003]
　XIONG Wancheng,PING Guanfang,HE Dedong,et al.Effect of triptolide on resistance of human colorectal cancer cell line to oxaliplation[J].Journal of Xinxiang Medical University,2023,40(12):613.[doi:10.7683/xxyxyxb.2023.07.003]

更新日期/Last Update: 2019-12-05